COO Cooper Companies Inc.

CooperCompanies 4-for-1 Stock Split Effective Friday (2/16)

CooperCompanies 4-for-1 Stock Split Effective Friday (2/16)

SAN RAMON, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is expected to begin on a stock split-adjusted basis at market open on Tuesday, February 20, 2024, under the existing trading symbol “COO”. The stock split supports Cooper’s desire to make ownership of its stock more accessible to employees and investors.

Cooper previously announced on its fourth quarter 2023 earnings release dated December 7, 2023, that it would implement the stock split of its outstanding shares of common stock, as approved by its board of directors. The stock split is a mandatory exchange. The new CUSIP number for Cooper’s common stock following the split will be 216648501.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies (“Cooper”) has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit .

Forward-Looking Statements

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Certain statements including, without limitation, statements regarding the expected timing and impact of the stock split are “forward-looking statements” that are subject to risks and uncertainties. Various important factors could cause results to differ materially, including the risks identified in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended October 31, 2023, as such disclosures may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663



EN
15/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

 PRESS RELEASE

CooperCompanies Announces First Quarter 2026 Results

CooperCompanies Announces First Quarter 2026 Results SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Recon...

 PRESS RELEASE

CooperCompanies Announces Release Date for First Quarter 2026

CooperCompanies Announces Release Date for First Quarter 2026 SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at . About Cooper...

 PRESS RELEASE

CooperCompanies to Present at the J.P. Morgan Healthcare Conference

CooperCompanies to Present at the J.P. Morgan Healthcare Conference SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Al White, President and CEO, will represent the Company in a session scheduled to begin at 5:15pm ET. A live and archived webcast of the event, where applicable, will be available on the CooperCompanies’ website at . About CooperCompaniesCooperCompanies (Nasdaq: COO) is a leading global medical de...

Cooper Companies Inc: 1 director

A director at Cooper Companies Inc bought 1,784 shares at 84.060USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Dire...

CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors Enters into Cooperation Agreement with Browning West SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company’s Board of Directors (the “Board”) has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the “Cooperation Agreement”) with Browning West, LP. (“Browning West”). Mr....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch